HUE043086T2 - Az NXL104 gyógyszerészeti vegyület polimorf és pszeudopolimorf formái - Google Patents

Az NXL104 gyógyszerészeti vegyület polimorf és pszeudopolimorf formái

Info

Publication number
HUE043086T2
HUE043086T2 HUE17182561A HUE17182561A HUE043086T2 HU E043086 T2 HUE043086 T2 HU E043086T2 HU E17182561 A HUE17182561 A HU E17182561A HU E17182561 A HUE17182561 A HU E17182561A HU E043086 T2 HUE043086 T2 HU E043086T2
Authority
HU
Hungary
Prior art keywords
nxl104
polymorphic
pharmaceutical compound
pseudopolymorphic forms
pseudopolymorphic
Prior art date
Application number
HUE17182561A
Other languages
English (en)
Inventor
Sisir Bhattacharya
Alain Bonnet
Mahendra G Dedhiya
Veronique Ducandas
Alexandre Giuliani
Alain Priour
Valerie Ravaux
Peter Spargo
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE043086(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of HUE043086T2 publication Critical patent/HUE043086T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE17182561A 2009-10-09 2010-10-08 Az NXL104 gyógyszerészeti vegyület polimorf és pszeudopolimorf formái HUE043086T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0904864A FR2951171A1 (fr) 2009-10-09 2009-10-09 Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US26366309P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
HUE043086T2 true HUE043086T2 (hu) 2019-08-28

Family

ID=42154208

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17182561A HUE043086T2 (hu) 2009-10-09 2010-10-08 Az NXL104 gyógyszerészeti vegyület polimorf és pszeudopolimorf formái

Country Status (22)

Country Link
US (5) US8471025B2 (hu)
EP (3) EP3269717B9 (hu)
JP (4) JP6072540B2 (hu)
KR (4) KR101817811B1 (hu)
CN (3) CN102834395B (hu)
AU (1) AU2010304974B2 (hu)
BR (2) BR122019021689B8 (hu)
CA (1) CA2716914C (hu)
CY (1) CY1121583T1 (hu)
DK (1) DK3269717T5 (hu)
ES (2) ES2721228T5 (hu)
FI (1) FI3269717T4 (hu)
FR (1) FR2951171A1 (hu)
HU (1) HUE043086T2 (hu)
IL (3) IL218565A0 (hu)
MX (1) MX2012003730A (hu)
MY (1) MY174776A (hu)
PL (1) PL3269717T5 (hu)
PT (1) PT3269717T (hu)
RU (1) RU2727509C2 (hu)
SI (1) SI3269717T2 (hu)
WO (1) WO2011042560A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096798A1 (en) * 2009-02-23 2010-08-26 Forest Laboratories Holdings Limited Novel cephem compounds useful for the treatment of bacterial infections
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX338610B (es) * 2011-07-26 2016-04-25 Wockhardt Ltd Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
EP2748165B1 (en) * 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8927724B2 (en) 2012-03-30 2015-01-06 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8962843B2 (en) 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
CN105859609B (zh) 2012-05-30 2019-04-09 明治制果药业株式会社 β-内酰胺酶抑制剂及其制备方法
NZ711326A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
RU2625304C2 (ru) * 2013-03-08 2017-07-13 Вокхардт Лимитед Способ получения (2s,5r)-7-оксо-6-сульфоокси-2-[((3r)-пирролидин-3-карбонил)гидразинокарбонил]-1,6-диазабицикло[3.2.1]октана
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
MY193210A (en) 2013-09-24 2022-09-26 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US10131665B2 (en) 2013-10-08 2018-11-20 Meiji Seika Pharma Co., Ltd. Processes for producing diazabicyclooctane compounds
CN106029068A (zh) * 2014-02-20 2016-10-12 沃克哈特有限公司 包含抗菌剂的药物组合
EP3212238A1 (en) 2014-10-28 2017-09-06 Sandoz AG Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
WO2017025526A1 (en) * 2015-08-10 2017-02-16 Sandoz Ag Form c of avibactam sodium
CN107325096B (zh) * 2016-04-29 2020-11-03 正大天晴药业集团股份有限公司 一种阿维巴坦单钠盐的结晶
KR102482826B1 (ko) * 2016-08-26 2022-12-28 산도즈 아게 아비박탐 유리 산
CN114591223A (zh) 2016-09-16 2022-06-07 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
CN107880042A (zh) * 2016-09-30 2018-04-06 上海复星星泰医药科技有限公司 阿维巴坦钠及其中间体化合物的制备方法
AU2018219569B2 (en) * 2017-02-08 2021-11-11 Sandoz Ag Process for the preparation of crystalline form C of avibactam sodium
KR102611447B1 (ko) 2017-05-08 2023-12-06 엔타시스 테라퓨틱스, 인크. 박테리아 감염을 치료하는 화합물 및 방법
WO2019064065A1 (en) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
EP3687993A1 (en) * 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
US10759800B2 (en) * 2017-09-27 2020-09-01 Fedora Pharmaceuticals Inc. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN107827886B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种高纯度阿维巴坦的精制制备工艺
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN107936017A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过结晶制备晶型a或晶型d阿维巴坦产品的方法
CN107935945A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过反应制备晶型a或晶型d阿维巴坦产品的方法
CN110078728B (zh) * 2019-05-23 2020-10-23 江西富祥药业股份有限公司 一种阿维巴坦中间体、制备方法及其应用
CN113105455B (zh) * 2020-01-10 2024-05-17 四川科伦药物研究院有限公司 晶型b阿维巴坦钠的制备方法
CN111689964A (zh) * 2020-07-21 2020-09-22 海南海灵化学制药有限公司 一种阿维巴坦纳的稳定晶型以及制备方法
CN114249729A (zh) * 2020-09-23 2022-03-29 四川科伦药物研究院有限公司 一种通过反应结晶制备晶型b阿维巴坦钠的方法
CN115677697B (zh) * 2022-09-19 2024-08-06 瑞阳制药股份有限公司 粒度可调控且流动性好的b晶型阿维巴坦钠析晶方法
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197454B1 (ko) * 1993-12-29 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 디아자비시클릭 뉴로키닌 길항제
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
ES2323759T3 (es) * 2000-08-10 2009-07-24 Takeda Pharmaceutical Company Limited Compuesto de fosfonocefem.
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US20080081829A1 (en) * 2006-09-28 2008-04-03 Med Institute, Inc Medical Device Including an Anesthetic and Method of Preparation Thereof
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP3260551A1 (en) † 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
MX2012003411A (es) * 2009-09-21 2012-04-30 Forest Lab Holdings Ltd Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Also Published As

Publication number Publication date
EP3269717A1 (en) 2018-01-17
KR101817811B1 (ko) 2018-01-11
BR122019021689B8 (pt) 2021-05-25
US8835455B2 (en) 2014-09-16
PL3269717T3 (pl) 2019-07-31
IL239663A0 (en) 2015-08-31
ES2721228T5 (es) 2023-10-30
IL259296A (en) 2018-07-31
US20140349967A1 (en) 2014-11-27
EP3269717B9 (en) 2023-08-09
CN109824668A (zh) 2019-05-31
BR112012007976B1 (pt) 2020-03-03
RU2015137928A3 (hu) 2019-04-04
SI3269717T2 (sl) 2023-09-29
RU2012118247A (ru) 2013-11-20
DK3269717T3 (en) 2019-04-23
KR20200010586A (ko) 2020-01-30
US9062053B2 (en) 2015-06-23
JP2018123151A (ja) 2018-08-09
RU2015137928A (ru) 2018-12-25
US8471025B2 (en) 2013-06-25
EP3505518A1 (en) 2019-07-03
US20110152311A1 (en) 2011-06-23
AU2010304974A1 (en) 2012-04-05
PT3269717T (pt) 2019-05-16
DK3269717T4 (da) 2023-06-26
MX2012003730A (es) 2012-10-03
AU2010304974B2 (en) 2014-10-23
JP2016029082A (ja) 2016-03-03
CA2716914A1 (en) 2011-04-09
US9580424B2 (en) 2017-02-28
KR20180067717A (ko) 2018-06-20
EP2486038B1 (en) 2017-08-30
JP6630391B2 (ja) 2020-01-15
JP6321853B2 (ja) 2018-05-09
WO2011042560A1 (en) 2011-04-14
CN102834395B (zh) 2016-06-29
US20170210742A1 (en) 2017-07-27
CY1121583T1 (el) 2020-05-29
BR122019021689B1 (pt) 2020-10-27
FR2951171A1 (fr) 2011-04-15
JP6197170B2 (ja) 2017-09-20
KR20120106720A (ko) 2012-09-26
CN104592229A (zh) 2015-05-06
CA2716914C (en) 2020-10-27
MY174776A (en) 2020-05-14
ES2645110T3 (es) 2017-12-04
KR20170134791A (ko) 2017-12-06
ES2721228T3 (es) 2019-07-29
IL259296B (en) 2021-10-31
JP2013507346A (ja) 2013-03-04
RU2727509C2 (ru) 2020-07-22
EP2486038A1 (en) 2012-08-15
US20150246920A1 (en) 2015-09-03
DK3269717T5 (da) 2023-11-27
EP3269717B1 (en) 2019-02-27
FI3269717T4 (fi) 2023-08-31
EP3269717B2 (en) 2023-06-14
US20130267480A1 (en) 2013-10-10
JP2017149754A (ja) 2017-08-31
JP6072540B2 (ja) 2017-02-01
IL218565A0 (en) 2012-05-31
CN102834395A (zh) 2012-12-19
SI3269717T1 (sl) 2019-05-31
PL3269717T5 (pl) 2023-09-18

Similar Documents

Publication Publication Date Title
SI3269717T2 (sl) Polimorfne in psevdopolimorfne oblike farmacevtske sestavine NXL104
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1175470A1 (en) Aryl and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
EP2515713A4 (en) STABILIZATION OF OBJECTS
EP2438246A4 (en) CONSTRUCTION ASPECTS
IL258239A (en) and st–methods producing polymorphs of 246 for their preparation
EP2381786A4 (en) DARUNAVIR POLYMORPHS
GB2474075B (en) Display assembly having different types of display
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2231687A4 (en) NEW DERIVATIVES OF ACYL-CYANPYRROLIDINES
EP2515709A4 (en) STABILIZATION OF OBJECTS
EP2400848A4 (en) CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
EP2490541A4 (en) 2-SUBSTITUTED ETHYL HYLTHIAZONE DERIVATIVES AND THEIR USE
EP2415774A4 (en) PRASUGREL BROMHYDRATE CRYSTALS
EP2478359A4 (en) METHOD FOR IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
GB0910078D0 (en) Uses of mannose-6-phosphate
HK1244484B (zh) 藥物化合物nxl104的多晶型形式和假多晶型形式
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYLBENZENES
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
TWM372743U (en) Improved structure of Kendama
EP2404608A4 (en) COMBINATION USE OF CHOLESTANOL DERIVATIVE
TWM365675U (en) Improved structure of teapoy
GB0920625D0 (en) Ace of plugs
GB0821710D0 (en) Derivatives of dihydroindolone